SCHEMBL5137595

SCHEMBL5137595

CCCCn1c(CN(CCc2cccc(OC)c2OC)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.55
C5AR1 P21730 1/20 0.51
HTR2A P28223 9/20 0.44
HTR2B P41595 9/20 0.44
HTR2C P28335 8/20 0.44
POLB P06746 1/20 0.44
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
ADRB1 P08588 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
DRD1 P21728 1/20 0.41
DRD4 P21917 1/20 0.41
SLC6A2 P23975 1/20 0.41
ADRA1D P25100 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137303 0.94 TP53 (0.51) TP53C5AR1HTR2AHTR2BHTR2C
SCHEMBL5137163 0.93 TP53 (0.53) TP53C5AR1HTR2AHTR2BHTR2C
SCHEMBL5135001 0.89 TP53 (0.54) TP53C5AR1HTR2AHTR2BHTR2C
SCHEMBL5136199 0.89 HTR2A (0.47) TP53C5AR1HTR2AHTR2BHTR2C
SCHEMBL5135525 0.89 C5AR1 (0.53) TP53C5AR1HTR2AHTR2BHTR2C
SCHEMBL5137546 0.88 HTR2A (0.49) TP53C5AR1HTR2AHTR2BHTR2C
SCHEMBL5134933 0.88 C5AR1 (0.49) TP53C5AR1HTR2AHTR2BHTR2C
SCHEMBL5137371 0.88 C5AR1 (0.49) TP53C5AR1HTR2AHTR2BHTR2C
SCHEMBL5134549 0.88 C5AR1 (0.50) TP53C5AR1HTR2AHTR2BHTR2C
SCHEMBL5135655 0.88 C5AR1 (0.54) TP53C5AR1HTR2AHTR2BHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed